This high-yield episode breaks down exactly why Lp(a) is gaining attention as a critical cardiovascular risk factor. It's genetically determined, stable for life, and not modified by lifestyle. Dr. Beg reviews who needs testing, when to test, and how Lp(a) contributes to atherosclerosis, inflammation, and calcific aortic valve disease.

We’ll also dive into current and emerging treatment options including PCSK9 inhibitors and promising RNA-based therapies like Pelacarsen and Olpasiran and clarify when Lp(a) testing is essential for your board prep, LKA, or everyday patient care.

Perfect for:
• Internal medicine & endocrine board review
• LKA prep
• Clinicians managing lipid disorders or ASCVD risk

Want detailed episode notes? Subscribe at ezendoprep.com